ClinicalTrials.gg
CompletedNCT07930286Updated Nov 12, 2026

Silicone Gel Versus White Petrolatum After Fractional CO₂ Laser

A Phase 4 interventional study of Silicone Gels and Petrolatum Ointment in Acne Scars and Acne Scars - Atrophic, sponsored by University Medical Center Ho Chi Minh City (UMC). Completed at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University Medical Center Ho Chi Minh City (UMC) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2025, registered Oct 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare the effectiveness and safety of silicone gel and white petrolatum for skin recovery after fractional CO₂ laser treatment in patients with atrophic acne scars.

The main questions it aims to answer are:

  • Does silicone gel improve skin-barrier recovery and shorten healing time compared with white petrolatum?
  • Does silicone gel provide better acne scar improvement and patient satisfaction?
  • Are there differences in side effects, such as redness, acneiform eruptions, and post-inflammatory hyperpigmentation?

Researchers will compare silicone gel with white petrolatum in 39 patients using a randomized, double-blind, split-face design.

Participants will:

  • Receive one full-face fractional CO₂ laser treatment for atrophic acne scars.
  • Apply silicone gel to one randomly assigned side of the face and white petrolatum to the other side.
  • Attend follow-up visits at weeks 1, 2, and 6.
  • Undergo assessments of acne scar severity, skin hydration, transepidermal water loss, redness, pigmentation, healing time, and adverse effects.
  • Report their skin sensations and satisfaction with each treatment.
02

Conditions studied

  • Acne Scars
  • Acne Scars - Atrophic

Browse trials for

Keywords

  • acne scars
  • fractional CO₂ laser
  • silicone gel
  • white petrolatum
  • wound healing
  • patient satisfaction
03

In context

Patient Satisfaction

880 studies on the registry are indexed under Patient Satisfaction; 204 are open to participants now.

This study's enrollment of 39 is below the median of 96 across 626 interventional studies indexed under Patient Satisfaction.

Browse Patient Satisfaction studies →

Lead sponsor

University Medical Center Ho Chi Minh City (UMC) is the lead sponsor of 35 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥ 18 years) with clinically comparable bilateral atrophic acne scars indicated for fractional CO₂ laser

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Keloidal tendency
  • Diabetes mellitus
  • Chronic infection
  • Anticoagulant use
  • Active skin or infection
  • History of herpes simplex or of filler within 12 months
  • History of other scar treatment within 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Silicone gel

    After topical anaesthesia (EMLA 5%, 30 minutes) and antisepsis, full-face fractional CO₂ laser was performed by the treating physician following a standard protocol, using the AcuPulse system (Lumenis) with the Deep FX handpiece (120 µm spot, Superpulse mode) at 17.5-22.5 mJ per microbeam and 5% density in a single pass, identical on both facial halves. Immediately after laser, the side to receive each product (silicone gel or white petrolatum) was determined by random draw: a container held six lots numbered 1 to 6; an odd number assigned silicone gel to the right half and white petrolatum to the left, and an even number assigned the reverse. The intervention was silicone gel (Stratacel; Stratpharma AG, Basel, Switzerland), a Class B medical device licensed by the Ministry of Health of Vietnam

    Drug: Silicone Gels

  • Placebo comparator
    White petrolatum

    After topical anaesthesia (EMLA 5%, 30 minutes) and antisepsis, full-face fractional CO₂ laser was performed by the treating physician following a standard protocol, using the AcuPulse system (Lumenis) with the Deep FX handpiece (120 µm spot, Superpulse mode) at 17.5-22.5 mJ per microbeam and 5% density in a single pass, identical on both facial halves. Immediately after laser, the side to receive each product (silicone gel or white petrolatum) was determined by random draw: a container held six lots numbered 1 to 6; an odd number assigned silicone gel to the right half and white petrolatum to the left, and an even number assigned the reverse. The comparator was white petrolatum (Vaseline; Boston plant). Both are indicated for application to injured or wounded skin .

    Drug: Petrolatum Ointment

Interventions

  • DrugSilicone Gels

    The intervention was silicone gel (Stratacel; Stratpharma AG, Basel, Switzerland), a Class B medical device licensed by the Ministry of Health of Vietnam, and the comparator was white petrolatum (Vaseline; Boston plant). Both are indicated for application to injured or wounded skin

  • DrugPetrolatum Ointment

    The intervention was silicone gel (Stratacel; Stratpharma AG, Basel, Switzerland), a Class B medical device licensed by the Ministry of Health of Vietnam, and the comparator was white petrolatum (Vaseline; Boston plant). Both are indicated for application to injured or wounded skin

06

What researchers measure

Primary outcomes

  1. Scar severity

    Scar severity graded with the ECCA (Clinical Evaluation Scale for Acne Scars) score. Total score range: 0 to 540 points. Higher scores mean more severe scarring.

    Time frame: Baseline and 1, 2, 6 weeks post-treatment

Secondary outcomes

  1. Overall improvement

    Overall improvement graded by two blinded dermatologists using the Physician Global Aesthetic Improvement Scale (PGAIS). The PGAIS typically uses a 5-point grading system comparing post-treatment results to baseline photographs or pre-treatment appearance; from "Much improved" to "Much worse".

    Time frame: Baseline and 1, 2, 6 weeks post-treatment

  2. Skin hydration

    Skin hydration index was measured with Corneometer probe (Courage + Khazaka)

    Time frame: Baseline and 1, 2, 6 weeks post-treatment

  3. Transepidermal Water Loss

    Transepidermal Water Loss index was measured with Tewameter probe (Courage + Khazaka)

    Time frame: Baseline and 1, 2, 6 weeks post-treatment

  4. Erythema

    Erythema index was measured with Mexameter probe (Courage + Khazaka)

    Time frame: Baseline and 1, 2, 6 weeks post-treatment

07

Study locations

1 site
  • University Medical Center
    Ho Chi Minh City, 70000, Vietnam
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to privacy concerns and institutional policies that restrict data sharing beyond the research team. Data were collected under a protocol that did not include participant consent for public or external data sharing.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Sep 2026, 16 months.

Of 24 phase 4 interventional studies under Patient Satisfaction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 12, 2026
StartActual
May 1, 2025
Primary completionActual
Sep 30, 2026
CompletionActual
Sep 30, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07930286
Lead sponsor
University Medical Center Ho Chi Minh City (UMC)
Responsible party
Ngô Anh Tuấn (Principal Investigator, University Medical Center Ho Chi Minh City (UMC)) — Principal investigator
First posted
Nov 12, 2026
Start date
May 1, 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion